Matches in Wikidata for { <http://www.wikidata.org/entity/Q96586832> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q96586832 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96586832 description "scientific article published on 14 June 2020" @default.
- Q96586832 description "wetenschappelijk artikel" @default.
- Q96586832 description "наукова стаття, опублікована 14 червня 2020" @default.
- Q96586832 name "Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan" @default.
- Q96586832 name "Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan" @default.
- Q96586832 type Item @default.
- Q96586832 label "Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan" @default.
- Q96586832 label "Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan" @default.
- Q96586832 prefLabel "Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan" @default.
- Q96586832 prefLabel "Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan" @default.
- Q96586832 P1433 Q96586832-338C754B-F37A-437D-9B96-6844AEBC601C @default.
- Q96586832 P1476 Q96586832-4D4D0D88-DFAE-4DD7-BE15-F12FF1E5DAA2 @default.
- Q96586832 P2093 Q96586832-43D5C191-0A74-4236-AFA5-1EFC80B8E7B1 @default.
- Q96586832 P2093 Q96586832-4A73BCA3-9E68-4EF2-8D42-AC4645E78084 @default.
- Q96586832 P2093 Q96586832-5C31466D-D790-4455-A480-2DACD94A7857 @default.
- Q96586832 P2093 Q96586832-87EB9245-A75D-417E-BFB6-60C11DC23CA9 @default.
- Q96586832 P2093 Q96586832-89716361-F964-47B7-81F9-9538FA3C6FD4 @default.
- Q96586832 P2093 Q96586832-E4B22D88-A3EA-42CB-85B7-2D1BB3E87698 @default.
- Q96586832 P31 Q96586832-CD9736DB-98E1-4EEF-AB86-FF8762970BC5 @default.
- Q96586832 P356 Q96586832-2792E6CB-F5B3-46F5-9641-C1BEF19E7668 @default.
- Q96586832 P577 Q96586832-539B6D57-1DE8-41D1-8CAF-39AA58807504 @default.
- Q96586832 P698 Q96586832-923F7FDD-B944-4827-B410-D78A3A46F88B @default.
- Q96586832 P921 Q96586832-51815887-9F2E-443F-94DE-D18A9F84BD24 @default.
- Q96586832 P921 Q96586832-554E8DCB-E243-4862-83E9-82164F55EB06 @default.
- Q96586832 P356 J.JFMA.2020.06.013 @default.
- Q96586832 P698 32553687 @default.
- Q96586832 P1433 Q15749621 @default.
- Q96586832 P1476 "Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan" @default.
- Q96586832 P2093 "Chen-Hua Liu" @default.
- Q96586832 P2093 "Chun-Jen Liu" @default.
- Q96586832 P2093 "Ding-Shinn Chen" @default.
- Q96586832 P2093 "Jia-Horng Kao" @default.
- Q96586832 P2093 "Pei-Jer Chen" @default.
- Q96586832 P2093 "Tung-Hung Su" @default.
- Q96586832 P31 Q13442814 @default.
- Q96586832 P356 "10.1016/J.JFMA.2020.06.013" @default.
- Q96586832 P577 "2020-06-14T00:00:00Z" @default.
- Q96586832 P698 "32553687" @default.
- Q96586832 P921 Q421862 @default.
- Q96586832 P921 Q55779873 @default.